RVMD241220P40000
- 0.35
- 0.000.00%
Revolution Medicines Newsroom
Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $62
Wedbush Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $67
Revolution Medicines Is Maintained at Outperform by Wedbush
Revolution Medicines Price Target Cut to $62.00/Share From $68.00 by Needham
Revolution Medicines Is Maintained at Buy by Needham
Revolution Medicines Analyst Ratings
H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $72
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $72
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $80
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $87
A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $68 to $80
Revolution Medicines' Promising RAS(ON) Portfolio and Strategic Growth Opportunities Justify Buy Rating
Revolution Medicines Is Maintained at Overweight by JP Morgan
Revolution Medicines Analyst Ratings
Promising Efficacy and Favorable Safety Profile Drive Buy Rating for Revolution Medicines' RMC-6236 in NSCLC Treatment
Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating
J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $63
BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $80
Bank of America Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)